{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-055248","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.774691+00:00","generated_at":"2026-05-20T02:45:57.747162+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TELA Bio appoints Jeffrey Blizard as President; Blizard resigns from Board","bullets":["Blizard resigned from Board effective June 2, 2025; no disagreement with company.","Blizard appointed President effective same date; Antony Koblish remains CEO, drops President title.","Annual base salary $475,000; target bonus 50% of salary; cash sign-on $150,000.","Equity grant: 154,100 stock options (4-yr vest) and 104,800 RSUs (4-yr annual vest).","Blizard previously Global Head of Surgical Sales at Abiomed (J&J); joined TELA Bio board June 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-055248","json":"https://secwatch.observer/filing/0001104659-25-055248.json","markdown":"https://secwatch.observer/filing/0001104659-25-055248.md","text":"https://secwatch.observer/filing/0001104659-25-055248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465925055248/0001104659-25-055248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465925055248/tm2516546d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:45:57.747162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"096de579f7","claim":"Antony Koblish changed role as President at TELA Bio, Inc..","evidence_excerpt":"Antony Koblish, the Company’s current President and Chief Executive Officer, will continue in his role as Chief Executive Officer, but as of the Effective Date will no longer hold the title of President.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465925055248/0001104659-25-055248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"relinquished"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"2bc679437f","claim":"Jeffrey Blizard resigned as Director at TELA Bio, Inc..","evidence_excerpt":"Jeffrey Blizard, a member of the Board of Directors (the “ Board ”) of TELA Bio, Inc. (the “ Company ”), tendered his resignation from the Board, effective as of June 2, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465925055248/0001104659-25-055248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c6da820e45","claim":"Jeffrey Blizard was appointed as President at TELA Bio, Inc..","evidence_excerpt":"the Board appointed Jeffrey Blizard as the new President of the Company, effective as of June 2, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465925055248/0001104659-25-055248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}